Latest News for: jnj

Edit

Final Trade: JNJ, NVO, UBER, BMY

CNBC 16 Dec 2025
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders ... .
Edit

NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of

Enid News & Eagle 24 Oct 2025
PARIS and CAMBRIDGE, Mass., Oct ... NANO –– NASDAQ.
Edit

NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head ...

Nasdaq Globe Newswire 24 Oct 2025
... announced updates to the JNJ-1900 (NBTXR3) clinical development program.
Edit

NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control (Form 6-K) (Nanobiotix SA)

Public Technologies 24 Oct 2025
NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control ... About JNJ-1900 (NBTXR3).
Edit

NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control (Nanobiotix SA)

Public Technologies 24 Oct 2025
Future guidance related to NANORAY-312 and other JNJ-1900 (NBTXR3)-related J&J-sponsored studies will be communicated by J&J ... About JNJ-1900 (NBTXR3). JNJ-1900 (NBTXR3) is a novel, potentially ...
Edit

NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer (Nanobiotix SA)

Public Technologies 02 Oct 2025
NANOBIOTIX ANNOUNCES FIRST DATA FROM PHASE 1 STUDY EVALUATING JNJ-1900 (NBTXR3) FOR PATIENTS WITH ESOPHAGEAL CANCER ... 6 patients in the study were medically indicated for and underwent surgery after treatment with CRT and JNJ-1900 (NBTXR3).
Edit

NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer

Nasdaq Globe Newswire 01 Oct 2025
Data presented at the 2025 Annual Meeting of the American Society for Radiation Oncology (ASTRO) on October 1st ... .
Edit

NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients

The Eagle-Tribune 01 Oct 2025
Treatment was well-tolerated and injection feasibility was ...
Edit

NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer (Form 6-K) (Nanobiotix SA)

Public Technologies 01 Oct 2025
About JNJ-1900 (NBTXR3). JNJ-1900 (NBTXR3) is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles that is administered via one-time intratumoral injection and activated by radiotherapy.
Edit

NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus

Caledonian Record 30 Sep 2025
Treatment remained well-tolerated with consistent injection ...
Edit

Why JNJ Stock Defines Shareholder Supremacy In Healthcare

Forbes 30 Sep 2025
This commitment to shareholder value has translated into exceptional market performance in 2025, with the stock delivering a remarkable ... .
Edit

NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC (Nanobiotix SA)

Public Technologies 30 Sep 2025
NANOBIOTIX ANNOUNCES UPDATED PHASE 1 RESULTS CONTINUING TO SUPPORT JNJ-1900 (NBTXR3) PLUS ANTI-PD-1 AS A POTENTIAL NEW 1L OR 2L+ OPTION IN ANTI-PD-1 NAÏVE OR RESISTANT R/M-HNSCC ... *** About JNJ-1900 (NBTXR3).
Edit

NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC (Form 6-K) (Nanobiotix SA)

Public Technologies 30 Sep 2025
JNJ-1900 (NBTXR3) activated by RT followed by anti-PD-1 was consistently well-tolerated and remained feasible in this heavily pre-treated patient population (n=103) ... About JNJ-1900 (NBTXR3). JNJ-1900 ...
Edit

NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a ...

Nasdaq Globe Newswire 29 Sep 2025
Data presented as a “Top-rated Abstract in Head and Neck Cancer” at the 2025 Annual Meeting of the American Society for Radiation Oncology (ASTRO) on September 29th ... .
Edit

NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in

Enid News & Eagle 17 Sep 2025
Data show a favorable safety profile and early efficacy ...

Article Search

tools
×
×
×
×